Publications by authors named "J Fujisawa"

We demonstrate that organic-inorganic interfacial charge-transfer transitions enable favourable photovoltaic conversion with CO-fixation products such as aromatic carboxylic acids, verifying a new possibility of CO-fixation products in the development of optoelectronic conversion materials.

View Article and Find Full Text PDF

Human T-cell leukemia virus type 1 (HTLV-1) infection is linked to the development of adult T-cell leukemia/lymphoma (ATLL) and the neuroinflammatory disease, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The HTLV-1 Tax oncoprotein regulates viral gene expression and persistently activates NF-κB to maintain the viability of HTLV-1-infected T cells. Here, we utilize a kinome-wide shRNA screen to identify the tyrosine kinase KDR as an essential survival factor of HTLV-1-transformed cells.

View Article and Find Full Text PDF

Immune responses in humanized mice are generally inefficient without co-transplantation of human thymus or HLA transgenes. Previously, we generated humanized mice via the intra-bone marrow injection of CD133+ cord blood cells into irradiated adult immunodeficient mice (IBMI-huNSG mice), which could mount functional immune responses against HTLV-1, although the underlying mechanisms were still unknown. Here, we investigated thymocyte development in IBMI-huNSG mice, focusing on the roles of human and mouse MHC restriction.

View Article and Find Full Text PDF

Veterinary medicine has made tremendous progress for domestic dogs, which are irreplaceable family members enriching human life. Nevertheless, no adequate supply system exists for their blood products. This study examined the synthesis, structure, safety, and efficacy of poly(2-ethyl-2-oxazoline)-conjugated porcine serum albumin (POx-PSA) as an artificial plasma expander for dogs.

View Article and Find Full Text PDF
Article Synopsis
  • - A small percentage of people infected with HTLV-1 can develop adult T-cell leukemia/lymphoma, a tough-to-treat disease, due to impaired CTLs, which are essential for fighting off the virus and cancer cells.
  • - Researchers used Japanese monkeys infected with STLV-1 (similar to HTLV-1) to test a therapeutic vaccine made from their own blood cells, which activated their CTLs and showed promising results in boosting immune responses.
  • - Vaccinated monkeys displayed increased STLV-1-specific CTL activity and a reduction in viral load after vaccination, but the immune responses peaked at 3-4 months and required additional boosters to maintain effectiveness over time.
View Article and Find Full Text PDF